PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with ...

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

BMY opened at $50.68 on Friday. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33. The company has a market cap of $103.11 billion, a price-to-earnings ratio of -11. ...

In the photo, the two-time Grammy winner, 31, is photographed in a casual outfit with a graphic t-shirt. The dark gray T-shirt is the cover art from Justin's third studio album, Believe ...

These V-neck undershirts were designed to eliminate ride-up and stay tucked, so you never have to worry about unwanted peeking from beneath your outer shirt. And even if you wear it on its own ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best medical stocks to buy according to billionaires. Some experts view medical ...

Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.33. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15.

Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Multi-Factor Investor model based on the published ...

We recently published a list of the 10 High Growth Dividend Paying Stocks to Invest in. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against ...

--Down 20.8% from its 52-week closing high of $63.11 on March 10, 2025 --Up 26.02% from its 52-week closing low of $39.66 on July 5, 2024 --Traded as low as $49.93; lowest intraday level since ...

A New York City federal court has dismissed a proposed class-action lawsuit against Bristol Myers Squibb that accused the drugmaker of deploying anticompetitive tactics to protect the market ...

Also Read: Europe Approves Bristol Myers’ Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer Opdivo plus Yervoy met the dual primary endpoints of progression-free survival (PFS ...